According to the higher relevant Alzheimer disease pathway and genes from network pharmacology results, two targets including amyloid beta precursor protein (APP) and glycogen synthase stimulate 3β (GSK3β) were further validated based on western blot experiments. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.